Quantum Biopharma (QNTM) Receivables (2018 - 2025)

Quantum Biopharma has disclosed Receivables across 8 years of filings, most recently posting $462106.0 for Q4 2025.

• Receivables for Q4 2025 came in at $462106.0, down 38.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $462106.0 (down 38.33% YoY), and the FY2025 annual result was $462106.0, down 38.33% from the prior year.
• Receivables came in at $462106.0 for Q4 2025 at Quantum Biopharma, down from $749356.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $749356.0 in Q4 2024 to a low of -$341916.0 in Q2 2021.
• The 5-year median for Receivables is $459817.0 (2023), against an average of $289473.0.
• Peak annual rise in Receivables reached 166.52% in 2021, while the deepest fall reached 170.39% in 2021.
• Quantum Biopharma's Receivables stood at $500964.0 in 2021, then soared by 49.46% to $748754.0 in 2022, then slumped by 38.89% to $457528.0 in 2023, then soared by 63.78% to $749356.0 in 2024, then slumped by 38.33% to $462106.0 in 2025.
• The last three Receivables figures came in at $462106.0 (Q4 2025), $749356.0 (Q4 2024), and $457528.0 (Q4 2023), per Business Quant data.